Previous 10 | Next 10 |
2023-07-10 13:00:09 ET Novartis ( NYSE: NVS ) said it has received expanded approval for its cholesterol-fighting drug Leqvio from US regulators. The FDA has approved Leqvio, also known as inclisiran, for the treatment of high LDL cholesterol in adults who are at increased risk ...
2023-07-07 18:36:46 ET Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical company Novartis (NYSE: NVS) on Friday. Following a judge's...
2023-07-07 11:30:25 ET The Association for Accessible Medicines, which has some of the world's largest generic drug manufacturers as members, is suing the Minnesota Attorney General over a new price control law. The suit, filed in federal court in the state, aims to block the price-cont...
2023-07-07 11:05:40 ET Novartis ( NYSE: NVS ) lost a patent ruling related to its blockbuster Entresto drug. A court found that claims of the '659 patent to be invalid for "lack of written description," according a court filing from the U.S. District Court for the District of ...
2023-07-06 14:48:32 ET Summary Johnson & Johnson's Supplemental Biologics Licensing Application of CARVYKTI was filed; approval would allow company to target a much earlier Multiple Myeloma patient population. Sales of CARVYTKI have not ramped up well since launch, but efforts...
2023-07-05 12:57:34 ET South Korea's Celltrion ( OTC:CONIF ) has launched a high-concentration, citrate-free formulated biosimilar of AbbVie's ( NYSE: ABBV ) Humira in the US. The biosimilar, which is called Yuflyma, was approved by the FDA in May. Yuflyma's list price is $6...
2023-07-02 04:45:00 ET Summary Cellular Biomedicine Group has out-licensed global rights to its two lead CAR-T candidates to Janssen Biotech for $245 million upfront. We have more on latest deals and financings from Sichuan Kelun-Biotech, Sichuan Kelun-Biotech, Lion TCR, Beijing B...
2023-07-01 16:00:00 ET Buoyed by booming sales of its diabetes drugs, Eli Lilly ( NYSE: LLY ) was the best performing large pharma or biotech in H1 2023, returning an impressive 28% . Coming in second, Vertex Pharmaceuticals ( VRTX ), helped by continued strong revenue f...
2023-06-30 07:55:08 ET Bausch + Lomb Corporation ( BLCO ) is set to pay $1.75B to acquire Xiidra, a dry-eye treatment from Novartis ( NVS ), The Wall Street Journal reported Friday, citing people familiar with the matter. The deal, the first major transaction under Bausch + Lo...
2023-06-29 12:00:00 ET Summary Where do you put money that you need? I have some big upcoming checks to write. Here are ideas for protecting earmarked principal. Activision My Activision Blizzard, Inc. ( ATVI ) calls will be fantastic if the FTC l...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...